drugset / Trial / NCT02464163
Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to investigate the safety and immunogenicity of a recombinant hemagglutinin (rHA) influenza vaccine derived from A/Anhui/1/2013 (H7N9) administered at 3 dose levels in adjuvanted (SE) rHA formulations and 1 dose levels in an unadjuvanted rHA formulation.
Timeline
- Start
- 2015-07
- Primary completion
- 2016-08
- Completion
- 2016-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PanBlok | Vaccine | 7.5 ug | Intramuscular |
| Subject | PanBlok | Vaccine | 15 ug | Intramuscular |
| Subject | PanBlok | Vaccine | 30 ug | Intramuscular |
| Subject | rHA adjuvant | Unknown | 2 % | Intramuscular |